CELLMED (셀메드)

Cellmed Orthocellular Medicine and Pharmaceutical Association (셀메드 세포교정의약학회)
권호 표지
DOI QR코드

DOI QR Code

Therapeutic Effect of Majoon Mundi and Qairooti Karnab in Dā al-Ṣadaf (Psoriasis): A Case Series

  • Received : 2019.09.26
  • Accepted : 2019.11.20
  • Published : 2019.11.29
Download PDF
⟨ Previous Next ⟩

Abstract

Introduction: Psoriasis is a major health concern around the world. Physicians of the Unani system of medicine have been treating psoriasis for centuries. Aim: The purpose of our study was to assess the effect of Majoon Mundi (a semisolid Unani medication intended for oral intake used as blood purifier) and Qairooti Karnab (a Unani medication in paste form intended for topical application used as emollient) in the treatment $na{\ddot{i}}ve$ psoriasis cases and to collect data to warrant further clinical trials. Material and Methods: Psoriasis cases were diagnosed clinically. Data were collected during treatment of five patients of psoriasis treated with the Majoon Mundi (oral intake of 5 gm twice daily with 200 ml of water for 12 weeks) and Qairooti Karnab (topical application on affected sites twice a day for 12 weeks). Patients were treated for 12 weeks. Treatment response was seen with clinical improvement in skin lesions and measurement of Psoriasis Area and Severity Index (PASI Scoring) before and after treatment. Results: Reduced PASI Score was observed in all five patients after 12 weeks of treatment [PASI before and after treatment was (mean${\pm}$SD) $20.7{\pm}4.6$ vs. $3.2{\pm}1.8$; p-value <0.05.]. Clinical improvement was noticed within an average of 4 weeks of treatment. Conclusion: Preliminary findings indicate the potential therapeutic role of Majoon Mundi and Qairooti Karnab in the treatment of psoriasis. Clinical trials based on this Unani pharmacopeial formulation should be conducted to explore the therapeutic potential of this formulation in psoriasis

Keywords

References

  1. Al, Tur S.H. et al. "Kamil Al-Tashkhis."(Lahore, India: Bu' IdaraTarjama al-Tibb).
  2. Aleem HMA, Khan N. Sharah-e-Rubaiyat: Tibb-e-Yousufi. (Lucknow, India: Munshi Naval Kishore).
  3. Ali., Syed Saiʻfuddin. Unani Adwiya Mufrada. (New Delhi, India: Taraqqi Urdu Beurea), 1984.
  4. Alim, Tabiba Shagufta. Amrad-i-Jild. (Aligarh, India: Saba), 2002.
  5. Anonymous. Qarabadin-i Majidi. (New Delhi, India: All India Tibbi Unani Congress.), 1951.
  6. Ansari S, Zeenat F, Ahmad W, Ahmad I. Therapeutics and Pharmacology of Gul-e-Surkh (Rosa Damascena Mill): An Important Unani Drug. International Journal of Advances in Pharmacy Medicine and Bioallied Sciences 2017:5(3):195-205
  7. Behl PN. Practice of Dermatology. 9th ed. (New Delhi, India: CBS Publishers and Distributor), 2000.
  8. Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. 2nd ed. (London, UK: MOSBY Elsevier). 2008.
  9. Bonifati C, Ameglio F. Cytokines in Psoriasis. International Journal of Dermatology 1999:38(4): 241-51. https://doi.org/10.1046/j.1365-4362.1999.00622.x
  10. British Association of Dermatologists. Psoriasis area and severity index (pasi) worksheet. Available at: http://www.bad.org.uk/shared/get-file.ashx?id=1654&itemtype=document. (Accessed on October 21, 2019).
  11. Danielsen K, Olsen AO, Wilsgaard T, Furberg AS. Is the Prevalence of Psoriasis Increasing? A 30-Year Follow-up of a Population-Based Cohort. The British journal of dermatology. 2013:168(6): 1303-10. https://doi.org/10.1111/bjd.12230
  12. Fredriksson T, Pettersson U. Severe Psoriasis - Oral Therapy with a New Retinoid. Dermatology.1978:157(4): 238-44. https://doi.org/10.1159/000250839
  13. Ghani. Khaza' in Al-Adwiya. (New Delhi, India: Iadra Kitab al-Shifa), 2011.
  14. Habashy J, Robles DT, James WD, Meffert J. Psoriasis. Available at: https://emedicine.medscape.com/article/1943419-overview (Accessed on October 21, 2019).
  15. Haslett C, Davidson S. Davidsons Principles and Practice of Medicine. (London, UK: Churchill Livingstone), 2002.
  16. Ibn Rushd, Abul Walid Mohammad. Kitab Al-Kulliyyat, Urdu Tarjamah. 2nd ed. (New Delhi, India: CCRUM Ministry of Kabeeruddin HM. Al Qarabadeen. (New Delhi, India: CCRUM.), 2006.
  17. Khan HA. Majma Al-Bahrain. (Lucknow, India: Matba Munshi Naval Kishore)
  18. Khan HMA. Akseer-e-Azam. Vol 4. (Kanpur, India: MatbaNizam).
  19. Law RM, Kwa PG. Dermatologic Disorders. In Pharmacotherapy: A Pathophysiological Approach, (New York, USA: McGraw-Hill Medical Publishing Division), 2011, 1693-1706.
  20. Lone AH, Ahmad T, Naiyar AH. Clinical Evaluation of Efficacy of Majoon Ushba and Roghane Hindi in the Management of Psoriasis: A Randomized Single-Blind, Placebo-Controlled Study. Journal of Ayurveda and Integrative Medicine. 2011: 2(1): 26-31. https://doi.org/10.4103/0975-9476.78188
  21. Majusi. Kamil Al-Sana. (Urdu Translation by Kanturi GH).Vol 1,2. (New Delhi, India: Idara Kitbab al- Shifa), 2010.
  22. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009:361(5):496-509. https://doi.org/10.1056/NEJMra0804595
  23. Papadakis MA, McPhee ST, Rabow MW. Current Medical Diagnosis & Treatment, (NY, USA: McGraw-hill Education) 2017.
  24. Peternel S, Prpic-Massari L, Guina T, Novak S, Brajac I, Kastelan M. Treatment of Severe Psoriasis with Infliximab: Report of Two Cases. Acta Dermatovenerol Croat. 2009;17(3):204-6.
  25. Rafiquddin M. Kanaz Al-Adwiya Mufrada. (Aligarh, India: Muslim University Press), 1985.
  26. Rahman, Mahfoozur et al. 12 Endocrine, Metabolic & Immune Disorders-Drug Targets Classical to Current Approach for Treatment of Psoriasis: A Review, 2012.
  27. Sainani GS. A.P.I. TextBook of Medicine, 6th Ed. (Mumbai, India: Association of Physicians of India), 1999.
  28. Sarac, G, Koca TT, Baglan T. A Brief Summary of Clinical Types of Psoriasis. North Clin Istanb. 2016: 3(1): 79-82.
  29. Schon MP1, Boehncke WH. Psoriasis. The New England journal of medicine 2005:352(18): 1899-1912. https://doi.org/10.1056/NEJMra041320